For research use only. Not for therapeutic Use.
VE-821（Cat No.:I000915）is a selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, an essential protein involved in the cellular response to DNA damage and replication stress. By inhibiting ATR, VE-821 sensitizes cancer cells to DNA-damaging agents, enhancing the efficacy of chemotherapy and radiation therapy. This compound is particularly relevant in treating tumors with deficiencies in DNA repair mechanisms, such as those with BRCA mutations. Preclinical studies have shown that VE-821 can improve therapeutic outcomes in various cancers by disrupting cell cycle regulation and promoting apoptosis in stressed cancer cells.
| Catalog Number | I000915 |
| CAS Number | 1232410-49-9 |
| Synonyms | 2-(aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol;sulfuric acid |
| Molecular Formula | C₁₈H₁₆N₄O₃S |
| Purity | ≥95% |
| Target | ATM/ATR |
| Solubility | DMSO 74 mg/mL; Water <1 mg/mL |
| Storage | -20°C |
| IC50 | 26 nM |
| IUPAC Name | 3-amino-6-(4-methylsulfonylphenyl)-N-phenylpyrazine-2-carboxamide |
| InChI | InChI=1S/C18H16N4O3S/c1-26(24,25)14-9-7-12(8-10-14)15-11-20-17(19)16(22-15)18(23)21-13-5-3-2-4-6-13/h2-11H,1H3,(H2,19,20)(H,21,23) |
| InChIKey | DUIHHZKTCSNTGM-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N |
| Reference | </br>1:Sulfoximines as ATR inhibitors: Analogs of VE-821. Hendriks CMM, Hartkamp J, Wiezorek S, Steinkamp AD, Rossetti G, Lüscher B, Bolm C.Bioorg Med Chem Lett. 2017 Apr 8. pii: S0960-894X(17)30401-8. doi: 10.1016/j.bmcl.2017.04.026. [Epub ahead of print] PMID: 28479198 </br>2:Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821. Colis LC, Herzon SB.Bioorg Med Chem Lett. 2016 Jul 1;26(13):3122-6. doi: 10.1016/j.bmcl.2016.04.090. Epub 2016 Apr 30. PMID: 27177826 </br>3:VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells irradiated with high LET radiation. Fujisawa H, Nakajima NI, Sunada S, Lee Y, Hirakawa H, Yajima H, Fujimori A, Uesaka M, Okayasu R.Radiat Oncol. 2015 Aug 19;10:175. doi: 10.1186/s13014-015-0464-y. PMID: 26286029 Free PMC Article</br>4:ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Jossé R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, Barnes CS, Jones J, Charlton P, Pollard JR, Morris J, Doroshow JH, Pommier Y.Cancer Res. 2014 Dec 1;74(23):6968-79. doi: 10.1158/0008-5472.CAN-13-3369. Epub 2014 Sep 30. PMID: 25269479 Free PMC Article</br>5:Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): phosphoproteomic analysis. Šalovská B, Fabrik I, Ďurišová K, Link M, Vávrová J, Řezáčová M, Tichý A.Int J Mol Sci. 2014 Jul 7;15(7):12007-26. doi: 10.3390/ijms150712007. PMID: 25003641 Free PMC Article</br>6:Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Vávrová J, Zárybnická L, Lukášová E, Řezáčová M, Novotná E, Sinkorová Z, Tichý A, Pejchal J, Durišová K.Radiat Environ Biophys. 2013 Nov;52(4):471-9. doi: 10.1007/s00411-013-0486-5. Epub 2013 Aug 11. PMID: 23934411 </br>7:The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB.Cancer Biol Ther. 2012 Sep;13(11):1072-81. doi: 10.4161/cbt.21093. Epub 2012 Jul 24. PMID: 22825331 Free PMC Article |
